Prognostic Impact of LAG-3 mRNA Expression in Early Breast Cancer

<b>Background:</b> Monoclonal antibodies against PD-1 or PD-L1 have been established in clinical practice for the treatment of both early and advanced/metastatic triple-negative breast cancer. Beyond the established immune checkpoints (ICPs) (PD-1 and CTLA-4), additional ICPs, such as ly...

詳細記述

書誌詳細

出版年:	Biomedicines
主要な著者:	Anne-Sophie Heimes, Katrin Almstedt, Slavomir Krajnak, Anne Runkel, Annika Droste, Roxana Schwab, Kathrin Stewen, Antje Lebrecht, Marco J. Battista, Walburgis Brenner, Annette Hasenburg, Mathias Gehrmann, Jan G. Hengstler, Marcus Schmidt
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2022-10-01
主題:	LAG-3 immune checkpoints immunotherapy breast cancer
オンライン･アクセス:	https://www.mdpi.com/2227-9059/10/10/2656